<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/62211B96-56AF-4672-8BA7-754E3F0AC07B"><gtr:id>62211B96-56AF-4672-8BA7-754E3F0AC07B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1000733"><gtr:id>4ABD1951-C76E-4F7F-9117-1364094EF0BE</gtr:id><gtr:title>RNA processing proteins and neurodegeneration: exploring mechanisms and modelling disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1000733</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Recent genetic and pathological discoveries have placed the RNA-processing proteins, TDP-43 and FUS, centre stage in the pathogenesis of ALS and FTLD-U. Here we present evidence that FUS and TDP-43 mislocalise and aggregate in FTLD-U patients with PGRN mutations. Aberrant processing of transcripts may cause neurodegenration due to a loss of function; however, these proteins also aggregate in affected neurons and may cause a toxic gain in function. The main aim of this proposal is to generate cellular and animal models to determine which mechanism is predominant (or whether both are necessary) and identify the events that initiate neurodegeneration. We will: _ Generate and characterise cellular models of PGRN, TDP-43 and FUS mediated neurodegeneration. _ Generate and characterise zebrafish and mouse models of PGRN, TDP-43 and FUS mediated neurodegeneration. _ Identify the physiological DNA and RNA binding targets of TDP-43 and FUS in cells and animal tissues. _ Define the transcriptional and proteomic signatures for loss and/or gain of function for PGRN, TDP-43 and FUS in cellular and animal models. _ Interrogate FTLD and ALS nervous tissues for loss and/or gain of function transcriptomic or proteomic signatures and compare these to other neurodegenerative disorders _ Identify the major sites of in vivo phosphorylation of TDP-43 and FUS, the kinases responsible and the functional consequences of these post translational modifications.</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1626335</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2145AFFE-90FE-48B5-A5F3-C04C86DECE00</gtr:id><gtr:impact>Public lecture on the genetics and biology of motor neuron disease</gtr:impact><gtr:outcomeId>58c93f4e8924f4.27061276</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>0D56BF2C-8383-404E-B956-4D8ED9AF0FD6</gtr:id><gtr:impact>Our Open Day is for patients and carers with approximately 150 attendees. We organise 8 laboratory demonstrations presented by PhD students and postdoctoral researchers around which small groups (6-8 persons) circulate. We also have a group of about 12 sixth form students who perform a laboratory experiment. At the end of the day the sixth formers present their results to the who audience and this is followed by an &amp;quot;Any Questions&amp;quot; session with clinical and non-clinical experts answering questions from the visitors.

The Open Day has now been run on three occasions and each time has received universal acclaim from visitors. The report is also made available on our web site.</gtr:impact><gtr:outcomeId>4C98074F446</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Peterborough</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>D180FDE5-C32D-4877-AABD-DFD2B8376E80</gtr:id><gtr:impact>Lectured to school students and informal chat

Enthusiastic discussion</gtr:impact><gtr:outcomeId>BB2D8E9C3C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented to Members of Parliament</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FC58433E-84BB-44D3-9589-96DFFBA013E3</gtr:id><gtr:impact>Presented to parliamentary parties

Legeislation changed</gtr:impact><gtr:outcomeId>4945B48396A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Use of Mass Spectrometry for Multi-site Phosphorylation Assays for Tau Protein</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>832E8AB0-852F-45BB-91BA-D2C8B8B0C8BC</gtr:id><gtr:impact>Poster presentation at International Conference on Alzheimer's Disease, Chicago

None</gtr:impact><gtr:outcomeId>154D6F59B6C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sleep and circadian rhythm disorder in Parkinson's Disease:  association with hallucinations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>B06290DC-D77D-4D11-95A1-62D59ED77E43</gtr:id><gtr:impact>A world conference on sleep.

Received a citation award.</gtr:impact><gtr:outcomeId>0041A34B2A3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>9EB7C719-D963-4F22-8DA4-9297224E9B63</gtr:id><gtr:impact>Each meeting has 40-60 attendees and lasts 1.5 hours with talk and questions

Patients have come to our laboratory open day and are actively fundraising to create a studentship</gtr:impact><gtr:outcomeId>tGyn6nSUUeL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture on motor neuron disease research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EC702FF1-2566-4E99-9237-0B14CE58F897</gtr:id><gtr:impact>I spoke at a dinner hosted by the MND Association for major donors at the Royal Institution</gtr:impact><gtr:outcomeId>58c93ff0bc3547.27040784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Multi-site Phosphorylation Assays for Tau Protein and their relevance to Alzheimer's disease and other neurological disorders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>8B0280A9-21B5-4DE4-8D4E-9D179C345519</gtr:id><gtr:impact>Poster presentation at American Society of Mass Spectrometry conference

None</gtr:impact><gtr:outcomeId>0E3C0190618</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>6A51F767-A7DB-4773-B22E-BA9449E6B240</gtr:id><gtr:impact>40-60 Patients and Carers lasting 1.5 hours of talk and discussion

Members of the audience are fundraising for a studentship for my laboratory</gtr:impact><gtr:outcomeId>sfMRufTmbZ7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Many media interviews TV, Radio, Newspapers, Radio</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>DF5C4AA6-12E6-4C8F-AC05-B6020DB822A4</gtr:id><gtr:impact>Many media interviews TV, Radio, Newspapers, Radio

Legislation modified</gtr:impact><gtr:outcomeId>9AE0CB30EDC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>666323</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant FP7</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Spanish National Research Council (CSIC)</gtr:fundingOrg><gtr:id>A9694535-2F71-46B8-8311-9579A1FD8883</gtr:id><gtr:outcomeId>YCL6KLgzZJE</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biomedical Sciences Institute PhD Studentship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>7A588E31-B2D5-45A8-BF44-025BD4C1A874</gtr:id><gtr:outcomeId>58c93d5ceb05d9.47554176</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>AD48EA36-9379-4140-80AE-7A8480862F88</gtr:id><gtr:outcomeId>58c93dbea62219.99794471</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>Liechtenstein, Principality of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Edmond J Safra Foundation</gtr:fundingOrg><gtr:id>E26417CA-BC36-4473-AAD1-41CC738AA6F7</gtr:id><gtr:outcomeId>58c93ccbc64304.85590454</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Case Studentship</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FDD7489A-4891-449F-BD22-E13FE23B8516</gtr:id><gtr:outcomeId>58c93c427e3264.75924272</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Psychiatry Research Trust</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>81BBC832-5651-4F8F-8E80-11A58AF8DC09</gtr:id><gtr:outcomeId>cp1b6N6ub5p</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>ALS Association</gtr:fundingOrg><gtr:id>F29EEBDC-B2FF-492F-9965-AF341B08A47E</gtr:id><gtr:outcomeId>sy7cgxbEKcY</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87502</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>1B8D6FE7-96A6-429C-AA42-8019B43DD35D</gtr:id><gtr:outcomeId>pVEA2SfsXd90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sumission to Parliamentary Science and Technology Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>F85F1692-E4D9-45A9-8057-C29DF60DC4F5</gtr:id><gtr:impact>Permitted the use of hybrid embryos in research in UK</gtr:impact><gtr:outcomeId>E70B2D9560D</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>536586DE-EABF-479F-A2FB-A2176E75FB6A</gtr:id><gtr:title>The evaluation of pain in amyotrophic lateral sclerosis: a case controlled observational study.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2bfcf87c109841d4d8f80742db55e3"><gtr:id>3a2bfcf87c109841d4d8f80742db55e3</gtr:id><gtr:otherNames>Wallace VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf04b08166.21868161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4ED4048-97BE-4932-B294-D841C236E9EC</gtr:id><gtr:title>Neurofilament subunit (NFL) head domain phosphorylation regulates axonal transport of neurofilaments.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d797bc249bf8a8ae3b3b16815fc8a71f"><gtr:id>d797bc249bf8a8ae3b3b16815fc8a71f</gtr:id><gtr:otherNames>Yates DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn><gtr:outcomeId>c4Amwjjc8H4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8573CEEF-B6D9-4754-93CB-B8B7E8F47C3B</gtr:id><gtr:title>Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6883810a16e61c37ff340736f6cdf792"><gtr:id>6883810a16e61c37ff340736f6cdf792</gtr:id><gtr:otherNames>van Rheenen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58a2d7f849c822.53353278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E73A6C2-9064-48D3-9562-2221F0044C9A</gtr:id><gtr:title>Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62f19520245730027ecb4972794f9589"><gtr:id>62f19520245730027ecb4972794f9589</gtr:id><gtr:otherNames>Vrabec K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d4623a5d1a59.09778202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FBCF863-9248-4244-A7C5-D7F1C5DBA173</gtr:id><gtr:title>Neuromuscular disease: new insights and avenues for therapy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544bcf019cb4a7.27593700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58CBE0A0-1009-4BA9-A9E6-47F8581A7140</gtr:id><gtr:title>C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a2fd7b1c29259.96416453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C5547DD-ACE0-4A47-AF4C-1BE8686FEA93</gtr:id><gtr:title>Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544bcf04de3ed0.40550380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14ABB821-F237-4811-865F-E20F1CFAE449</gtr:id><gtr:title>Screening for OPTN mutations in a cohort of British amyotrophic lateral sclerosis patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b92e53040750a2ced7a4b23f1f0a783"><gtr:id>9b92e53040750a2ced7a4b23f1f0a783</gtr:id><gtr:otherNames>Johnson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_12421_21_22892313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>837A65AA-D8B6-4BA2-959D-128E41385227</gtr:id><gtr:title>VCP mutations are not a major cause of familial amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca9888509a2e1aa2bdbb5ae3b44a8e0"><gtr:id>4ca9888509a2e1aa2bdbb5ae3b44a8e0</gtr:id><gtr:otherNames>Kwok CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>doi_55f9859851a8bffe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6812EB86-A6B2-494A-BC9A-2A6DABB4249B</gtr:id><gtr:title>Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>D85B3233FBD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AE2A3A7-E25B-4AA2-A645-CB2669BC29ED</gtr:id><gtr:title>ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d46239d884c7.36960805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD974B9B-D2DF-4761-9688-FC586A370B6C</gtr:id><gtr:title>The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a1becffcc1571868d22b707ce216d4c"><gtr:id>5a1becffcc1571868d22b707ce216d4c</gtr:id><gtr:otherNames>Wong CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d462397da5f1.15374831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B23CDF8-B333-473C-A62F-2C9C02C0A427</gtr:id><gtr:title>Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_12421_21_23053136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7C60F6-3018-4473-A706-F681129B0E74</gtr:id><gtr:title>A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac5f45d8a5f9965eb360b3f6697fe0a9"><gtr:id>ac5f45d8a5f9965eb360b3f6697fe0a9</gtr:id><gtr:otherNames>Akimoto C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>544bcf03a36e01.94761814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A1C193D-A9C4-48B4-8B55-123B71DC4AF7</gtr:id><gtr:title>Analysis of alternative splicing associated with aging and neurodegeneration in the human brain.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8c5b5cbc90e5661dfa072a51bb8ca2c"><gtr:id>b8c5b5cbc90e5661dfa072a51bb8ca2c</gtr:id><gtr:otherNames>Tollervey JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>pm_12421_21_21846794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92AFABF1-535E-483C-A220-10C969DCF477</gtr:id><gtr:title>Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf00f13c98.09263733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA33AD0-60C8-4465-9F41-3707425519DF</gtr:id><gtr:title>Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0355658aee7a567caa922e6adbda88b6"><gtr:id>0355658aee7a567caa922e6adbda88b6</gtr:id><gtr:otherNames>Zhang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_12421_ne_0076055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4168ED99-4E54-4C92-A632-8FE480DC6CCE</gtr:id><gtr:title>Establishing the UK DNA Bank for motor neuron disease (MND).</gtr:title><gtr:parentPublicationTitle>BMC genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d800fe2353c2fd435d4e9f68af2a0c5d"><gtr:id>d800fe2353c2fd435d4e9f68af2a0c5d</gtr:id><gtr:otherNames>Smith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2156</gtr:issn><gtr:outcomeId>56d462394ec2d4.90473666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAF438E3-90A1-4547-91C5-6343E18CBB61</gtr:id><gtr:title>Loss and gain of Drosophila TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d38dae4828ab28628becaabb9272ab97"><gtr:id>d38dae4828ab28628becaabb9272ab97</gtr:id><gtr:otherNames>Diaper DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_12421_hmg_ddt005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D21384F5-75D3-4D48-B843-105F0D40F8FF</gtr:id><gtr:title>FUS-SMN protein interactions link the motor neuron diseases ALS and SMA.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bf45674c6bde8beb118ae36344c14d8"><gtr:id>9bf45674c6bde8beb118ae36344c14d8</gtr:id><gtr:otherNames>Yamazaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_12421_21_23022481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68F962AC-6D50-4EEC-BD2A-389AAE526AAC</gtr:id><gtr:title>Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a46cc13f73dd87b9293e1cd22958c7c"><gtr:id>6a46cc13f73dd87b9293e1cd22958c7c</gtr:id><gtr:otherNames>Stepto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_540e16ae16a979aa1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B78E5FE-E5D7-4775-80E6-5CB0441751D7</gtr:id><gtr:title>TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>56d46237093897.21473834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>103B0012-9D52-4333-A15E-00DCEC8C70EB</gtr:id><gtr:title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf013e1c05.46260780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D190F1-7AA3-443E-BF7A-B61D1025BC6F</gtr:id><gtr:title>Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1db640afd979ca29b26d7ca6d657dfcf"><gtr:id>1db640afd979ca29b26d7ca6d657dfcf</gtr:id><gtr:otherNames>M?rotz GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12421_21_22258555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36086014-0F94-4C4E-A896-60552C9FE132</gtr:id><gtr:title>Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_540e16ae16a8e0adb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56E451B1-F412-4B93-8CB2-8886727367AE</gtr:id><gtr:title>No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc23875dbdf591dfec98dd2283598bc3"><gtr:id>cc23875dbdf591dfec98dd2283598bc3</gtr:id><gtr:otherNames>Goris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf0257e9b7.52663862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA2A2C26-9F4B-4E41-952B-1E352A953385</gtr:id><gtr:title>A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf02883315.60737102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43D2685D-63BA-4B05-8033-32742FA5BD97</gtr:id><gtr:title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da89c318f56fc7256d9d74b60d23229"><gtr:id>9da89c318f56fc7256d9d74b60d23229</gtr:id><gtr:otherNames>Sims R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa699e46a4a55.51168519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73E771E7-F51F-466C-846B-B8945083535B</gtr:id><gtr:title>Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>544bcf02dec130.64984146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A0AB2E4-1A68-48E8-BC6A-66DF264E911D</gtr:id><gtr:title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a7bfa806ecaa3aa93efd2103aa2e758"><gtr:id>0a7bfa806ecaa3aa93efd2103aa2e758</gtr:id><gtr:otherNames>Cirulli ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56d46237448962.78158026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE632D97-AFBA-4E59-BE12-1A8C64122EFD</gtr:id><gtr:title>Unpicking neurodegeneration in a dish with human pluripotent stem cells: one cell type at a time.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>544bcf0229e0f0.81404388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DB57263-F6BC-40DB-B708-AE84391EDED6</gtr:id><gtr:title>Non-nuclear Pool of Splicing Factor SFPQ Regulates Axonal Transcripts Required for Normal Motor Development.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/590ae3c09e86df575f4ab39639079647"><gtr:id>590ae3c09e86df575f4ab39639079647</gtr:id><gtr:otherNames>Thomas-Jinu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>5a34ec8b64a5e9.08083075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69AFC65E-A23F-45F4-B7A2-31FE41F58D97</gtr:id><gtr:title>Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18061332c54aaf54ab04a4a898d17ccc"><gtr:id>18061332c54aaf54ab04a4a898d17ccc</gtr:id><gtr:otherNames>Gomez-Deza J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d46238c9a2f3.14235257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>872C7F8B-836F-4137-84C9-79CFC0AB26F3</gtr:id><gtr:title>Comment on &amp;quot;Drug screening for ALS using patient-specific induced pluripotent stem cells&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>544bcf01f119e7.52699369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D34C654F-2488-4F54-8571-079BB507C568</gtr:id><gtr:title>Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b00d5c326cc86493597c8e738e15c9b9"><gtr:id>b00d5c326cc86493597c8e738e15c9b9</gtr:id><gtr:otherNames>Kim HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_12421_ature11922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DECDA403-93FA-4F05-9FEB-DCB794239D62</gtr:id><gtr:title>Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ecfd0497d0375c0a88359b331f4d279"><gtr:id>6ecfd0497d0375c0a88359b331f4d279</gtr:id><gtr:otherNames>Alami NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>544bcf031799a2.08217536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8BC4C09-AEAC-4C63-85F3-05936B326CD1</gtr:id><gtr:title>Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>58a2da95c283c4.62924411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB7EF709-0DBB-4178-89E8-E37B301D98F4</gtr:id><gtr:title>The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3617d8d8a839d289a3d354c415cb2d67"><gtr:id>3617d8d8a839d289a3d354c415cb2d67</gtr:id><gtr:otherNames>Lill CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>56d46238134629.13634024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4DBD8D3-69E0-4D73-91F2-A2F87F75EB1B</gtr:id><gtr:title>Mitochondrial abnormalities and disruption of the neuromuscular junction precede the clinical phenotype and motor neuron loss in hFUSWT transgenic mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc11642e0e6b6f151197c2c50c00f5f8"><gtr:id>cc11642e0e6b6f151197c2c50c00f5f8</gtr:id><gtr:otherNames>So E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a6796c4b437b0.61145578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD6D7FCE-31D6-40C7-8548-A5F642FBB0CB</gtr:id><gtr:title>Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6e554bc59d628ea7e59537f8090ec1c"><gtr:id>a6e554bc59d628ea7e59537f8090ec1c</gtr:id><gtr:otherNames>Gaastra B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58a2d69a1cd4d5.90060636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D725D2A4-FEE5-4C11-99EA-4F3047F14F3B</gtr:id><gtr:title>TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa1218e77e38a903ec46a6c73ad708a4"><gtr:id>fa1218e77e38a903ec46a6c73ad708a4</gtr:id><gtr:otherNames>Pensato V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d46239248903.24188323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9BB91C-F1D0-4D1B-BD05-AFC674D64C02</gtr:id><gtr:title>Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3dac9ccb09aac2d119921cddc240716"><gtr:id>d3dac9ccb09aac2d119921cddc240716</gtr:id><gtr:otherNames>Serio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_12421_1300398110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>115343E2-D7C2-415E-BD47-7FC9CEF6C7C9</gtr:id><gtr:title>An evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional regulator and its association to ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3108c31a0519408ba70fe51961bbba10"><gtr:id>3108c31a0519408ba70fe51961bbba10</gtr:id><gtr:otherNames>Savage AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf03736d30.04611140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7321F147-FAA9-40BA-8D90-980EA7B2A331</gtr:id><gtr:title>C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bc40f7ec51e8c45e1a0d464e57ce8e5"><gtr:id>4bc40f7ec51e8c45e1a0d464e57ce8e5</gtr:id><gtr:otherNames>Rooney J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58a2d5bd6dca00.65121282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD2EF87B-572E-4EE7-94FE-EC559C90C499</gtr:id><gtr:title>Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/648ce689029eb74519bb3610828d1173"><gtr:id>648ce689029eb74519bb3610828d1173</gtr:id><gtr:otherNames>van Eijk RPA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5aa699e5ebbea6.81534669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>751CFFE0-15F6-462F-9F9F-559213A33CF1</gtr:id><gtr:title>Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_12421_21_22961620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7482FE29-3627-4073-B9EE-8441B793E43E</gtr:id><gtr:title>Homozygosity analysis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5ecebb0a95326732850cb51e132dc6"><gtr:id>bb5ecebb0a95326732850cb51e132dc6</gtr:id><gtr:otherNames>Mok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf01c66b68.28467340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36757EB3-C327-4CF1-B67B-A138B8E73E9A</gtr:id><gtr:title>C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>544bcf04854020.50255754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C913FD6E-AB6C-49C6-9957-B318F1E7B60D</gtr:id><gtr:title>Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddda41cb956f24e278d3fa4457b83ecb"><gtr:id>ddda41cb956f24e278d3fa4457b83ecb</gtr:id><gtr:otherNames>Troakes C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>pm_12421_21_22934812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7851C794-97E3-440B-A91A-AA4A9AC455A3</gtr:id><gtr:title>Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d024ea21137b0b872fa04d61a2139840"><gtr:id>d024ea21137b0b872fa04d61a2139840</gtr:id><gtr:otherNames>Hortob?gyi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>ph2tqje8ycQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65E05D30-7D7B-42B8-99F2-B18A702F285C</gtr:id><gtr:title>Association studies indicate that protein disulfide isomerase is a risk factor in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca9888509a2e1aa2bdbb5ae3b44a8e0"><gtr:id>4ca9888509a2e1aa2bdbb5ae3b44a8e0</gtr:id><gtr:otherNames>Kwok CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>doi_12421_013_01_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52EFDEC6-AB10-476C-BC60-164C421C915A</gtr:id><gtr:title>ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6afa61e51d0b4f51e8d4cd8f47b871b"><gtr:id>d6afa61e51d0b4f51e8d4cd8f47b871b</gtr:id><gtr:otherNames>Arnold ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_12421_1222809110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0F1111E-48D8-4A1B-9EBA-F32AA4C89A9C</gtr:id><gtr:title>Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d961018c784ae275e4710ba79802b77"><gtr:id>9d961018c784ae275e4710ba79802b77</gtr:id><gtr:otherNames>Tudor EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>cvWfC5garsi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A4991E8-79C0-46B1-9700-9D479FF04C2A</gtr:id><gtr:title>Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d38dae4828ab28628becaabb9272ab97"><gtr:id>d38dae4828ab28628becaabb9272ab97</gtr:id><gtr:otherNames>Diaper DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_12421_hmg_ddt243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ADC03C9-D43C-46A4-B04B-2A6BF5AB3D9D</gtr:id><gtr:title>An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.</gtr:title><gtr:parentPublicationTitle>Neuropathology : official journal of the Japanese Society of Neuropathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddda41cb956f24e278d3fa4457b83ecb"><gtr:id>ddda41cb956f24e278d3fa4457b83ecb</gtr:id><gtr:otherNames>Troakes C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0919-6544</gtr:issn><gtr:outcomeId>pm_12421_21_22181065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>357971A0-79ED-4F2D-AF47-6C76DE81D8ED</gtr:id><gtr:title>Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d462387668a0.03122193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DFD5323-6698-460B-94F0-9BE6B13B3DFC</gtr:id><gtr:title>Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12421_21_22451909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C18AE0BB-C240-4CB7-B41A-F0C8804C9B4F</gtr:id><gtr:title>Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d46237ac4964.75802103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AFE3576-ECC5-4D72-ACE3-A82C9D2CC3B4</gtr:id><gtr:title>A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5aa699e3d49b28.83252519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74A9FCC9-4835-4BD4-A0F6-B4D8D59E5607</gtr:id><gtr:title>Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e078c74958f5d34c29d138c303e544f8"><gtr:id>e078c74958f5d34c29d138c303e544f8</gtr:id><gtr:otherNames>Landers JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>gCYQ71gdCPm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8831FF47-56E8-481A-8F19-FC3195A8FC7E</gtr:id><gtr:title>Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf045a5fe5.17451079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B45DD8-120E-4C43-AA7F-9D10E5F05A08</gtr:id><gtr:title>Maturation and electrophysiological properties of human pluripotent stem cell-derived oligodendrocytes.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a870ddbc6f40ddea0dc8f5449c90bb5d"><gtr:id>a870ddbc6f40ddea0dc8f5449c90bb5d</gtr:id><gtr:otherNames>Livesey MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>56d4623a8e71d3.84842728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B953A56-2B05-4933-B9A9-7E9CA70ED677</gtr:id><gtr:title>Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c3f5a5bc7ae9744e72b93546e48cb6f"><gtr:id>7c3f5a5bc7ae9744e72b93546e48cb6f</gtr:id><gtr:otherNames>Ahmeti KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>544bcf016e38a3.28501419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECCB5F43-3767-45E6-8EBA-BC203390D970</gtr:id><gtr:title>ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77bcf36f991f182856eac148a0a0aa02"><gtr:id>77bcf36f991f182856eac148a0a0aa02</gtr:id><gtr:otherNames>Stoica R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>544bcf042f8d38.13230496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC4D1089-E791-42A9-9524-7E2BDF5ED0B0</gtr:id><gtr:title>VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d0493aca288feb1c7b928115cc28a"><gtr:id>a19d0493aca288feb1c7b928115cc28a</gtr:id><gtr:otherNames>De Vos KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12421_21_22131369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FDF02E-CE4E-4D1E-A396-1F7C9A0C225E</gtr:id><gtr:title>pNfH is a promising biomarker for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11fc725be9193e0c1332b674cfa73b21"><gtr:id>11fc725be9193e0c1332b674cfa73b21</gtr:id><gtr:otherNames>Ganesalingam J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12421_21_23134506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FE403F8-A500-4655-8A25-38334FB29FBD</gtr:id><gtr:title>Capturing VCP: another molecular piece in the ALS jigsaw puzzle.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a11a5a9f39bc4fcc876c05fec866d8c0"><gtr:id>a11a5a9f39bc4fcc876c05fec866d8c0</gtr:id><gtr:otherNames>Shaw CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>W93T33aGQFJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58EE60B6-ECD2-43EE-AC01-FAE176601989</gtr:id><gtr:title>The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aa73e328eb61ebd7307a45f0b5976b5"><gtr:id>9aa73e328eb61ebd7307a45f0b5976b5</gtr:id><gtr:otherNames>Martin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5aa699e4e53521.11586011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F235F95-5BC0-4141-970E-7469C295BE88</gtr:id><gtr:title>Evidence of an environmental effect on survival in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c398b2323889da25d02c67f44bc8075"><gtr:id>4c398b2323889da25d02c67f44bc8075</gtr:id><gtr:otherNames>Keren N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf0400a993.74066423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C3CC00-7D2B-4CE4-BD0B-376774908CFE</gtr:id><gtr:title>ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_12421_hmg_ddt117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CD939D6-2CF4-4613-9FED-BDF198320968</gtr:id><gtr:title>Mutation analysis of VCP in British familial and sporadic amyotrophic lateral sclerosis patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8697d5274b04347d52a7ffa40e09bb2c"><gtr:id>8697d5274b04347d52a7ffa40e09bb2c</gtr:id><gtr:otherNames>Miller JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_12421_21_22789697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8AC8D5-0895-4795-BC8D-DEED3B9945B2</gtr:id><gtr:title>Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb87f110bb4914af0973f4d8272af1b6"><gtr:id>bb87f110bb4914af0973f4d8272af1b6</gtr:id><gtr:otherNames>Balendra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf03ce0f01.11996138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D2F6DB2-E27D-4B1A-9B65-D7CB76B81B74</gtr:id><gtr:title>Gene discovery in amyotrophic lateral sclerosis: implications for clinical management.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>58a2d505b97122.41464612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A296971A-5EC7-4B55-8EE4-0C16D24C91A8</gtr:id><gtr:title>NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa8dc20d96363a2f4e574a132c76feaf"><gtr:id>aa8dc20d96363a2f4e574a132c76feaf</gtr:id><gtr:otherNames>Kenna KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58a2d861aa1905.68112376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF59C6BD-FA10-4718-BD89-6CA0A8922C20</gtr:id><gtr:title>Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c562354aece4404287db767cad69712b"><gtr:id>c562354aece4404287db767cad69712b</gtr:id><gtr:otherNames>Rogelj B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>pm_12421_21_22934129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF7309A5-A98D-43BD-AE97-DDCC9771C01A</gtr:id><gtr:title>Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a68fd5b1ddbc5cb477a04d8d9b44b0b"><gtr:id>3a68fd5b1ddbc5cb477a04d8d9b44b0b</gtr:id><gtr:otherNames>?talekar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>56d462377e5135.87427190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69A40E10-FCFF-4A75-9F8C-7C8FDD2F479D</gtr:id><gtr:title>Tar DNA-binding protein-43 (TDP-43) regulates axon growth in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0737bcb5a8ebef94755f6214dfe82972"><gtr:id>0737bcb5a8ebef94755f6214dfe82972</gtr:id><gtr:otherNames>Tripathi VB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_540e16ae16aa32be5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61C1ED9C-2ADD-4062-83CA-A95785A68AF5</gtr:id><gtr:title>p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73513a14720b4cc1a2b1b206959c4d28"><gtr:id>73513a14720b4cc1a2b1b206959c4d28</gtr:id><gtr:otherNames>Al-Sarraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>DFqfegzz2TH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BAF950D-0AFD-4959-8D1C-273EF63EAFEA</gtr:id><gtr:title>Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/922738046572c98b4498b0faf60a5115"><gtr:id>922738046572c98b4498b0faf60a5115</gtr:id><gtr:otherNames>van der Kleij LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d462384a7143.14080160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>355D78B5-0CA1-4779-A1C3-78C87CE0DFFA</gtr:id><gtr:title>Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5aa699e3687533.67844697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4DDA7DA-348D-4FE2-A1EC-ADF2E8353208</gtr:id><gtr:title>ATXN2 trinucleotide repeat length correlates with risk of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6e29ff1fbfb82d08db9aa811d9c11"><gtr:id>fdc6e29ff1fbfb82d08db9aa811d9c11</gtr:id><gtr:otherNames>Sproviero W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5aa699e29b59d1.36739737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A38991D-4A3E-442C-9254-0A24B5E9B334</gtr:id><gtr:title>Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8fd6b166042712fd5babbc67312f707"><gtr:id>b8fd6b166042712fd5babbc67312f707</gtr:id><gtr:otherNames>Taes I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>DX2zb5A6RkF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2311B116-382E-4098-A276-6D85CE4D26F3</gtr:id><gtr:title>Novel mutations support a role for Profilin 1 in the pathogenesis of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5675ddabd33ae</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E4722E7-DE96-445E-BC02-AEB69D5AC207</gtr:id><gtr:title>C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca-permeable AMPA receptor-mediated excitotoxicity.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96d4ab24d1215f7ba80c2957f9f78cf3"><gtr:id>96d4ab24d1215f7ba80c2957f9f78cf3</gtr:id><gtr:otherNames>Selvaraj BT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa267dc6ef303.75039294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06FE1712-7D04-4722-BC9C-4CD03C994F08</gtr:id><gtr:title>RNA Misprocessing in-Linked Neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9adb0cf9c748d2062adf63457cc15ba4"><gtr:id>9adb0cf9c748d2062adf63457cc15ba4</gtr:id><gtr:otherNames>Barker HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>5aa699e5738790.24080771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6052165-B123-4C34-BC96-2155867083B1</gtr:id><gtr:title>TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations.</gtr:title><gtr:parentPublicationTitle>Neuropathology : official journal of the Japanese Society of Neuropathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0dfa7e2588f19b0ce627ccdbfa75a37"><gtr:id>a0dfa7e2588f19b0ce627ccdbfa75a37</gtr:id><gtr:otherNames>Maekawa S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0919-6544</gtr:issn><gtr:outcomeId>pm_12421_11_19496940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB664250-F3A3-4477-9976-708C8D4C3B12</gtr:id><gtr:title>Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29bb14781cddeeb34ff38065851a6ba1"><gtr:id>29bb14781cddeeb34ff38065851a6ba1</gtr:id><gtr:otherNames>Darovic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>56d46239a7cf84.98641392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4817C211-3689-4730-835F-71C60C8F949C</gtr:id><gtr:title>Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>doi_12421_013_03_003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>306E515B-517E-400B-84B1-7FBECD1AA828</gtr:id><gtr:title>Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52940ec2fe08219598d16e61c9f32c80"><gtr:id>52940ec2fe08219598d16e61c9f32c80</gtr:id><gtr:otherNames>Niblock M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d4623a192be3.89588407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC5A255E-F348-44CF-B27D-41BC795B5C98</gtr:id><gtr:title>Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56829c73b152e97680b79a2ccde32659"><gtr:id>56829c73b152e97680b79a2ccde32659</gtr:id><gtr:otherNames>Nishimura AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>k9uANyZWPek</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1000733</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>